The evolving role of PARP inhibitors in advanced ovarian cancer
Levva, Sofia, Skolariki, Aglaia, Sogka, Eleni, Bokas, Alexandros, Assi, Avraam, Pispirigou, Marianna K., Koliou, Panagiotis
Published in Forum of clinical oncology (01.08.2021)
Published in Forum of clinical oncology (01.08.2021)
Get full text
Journal Article
ATTAINMENT: A phase Ib trial of MDX-124, a first-in-class annexin-A1 targeting antibody, alone and in combination with anti-cancer treatments, in patients with advanced solid tumors
Palmer, Daniel H., Symeonides, Stefan N., Dempsey, Fiona C., Crichton, Scott J., Tennant, Colin, Wood, Christopher B., Knight, Ruth, Balabanova, Silviya, Upton, Clare, Low, Samantha S.P., Proudfoot-Jones, Jemma, Javed, Sohail Rooman, Skolariki, Aglaia, Blagden, Sarah Patricia
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma
Sacco, Joseph J, Harrington, Kevin Joseph, Olsson-Brown, Anna, Chan, Tze Y, Nenclares, Pablo, Leslie, Isla, Bommareddy, Praveen, Kalbasi, Alireza, Xie, Ben, Mishal, Moran, Cohan, David Michael, Skolariki, Aglaia, Middleton, Mark R.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A longitudinal retrospective case series of the real-world toxicities encountered among cancer patients receiving anti-PD-L1 checkpoint inhibitor immunotherapy
Boutis, Anastasios L., Skolariki, Aglaia, Diamantopoulos, Nikolaos, Bokas, Alexandros, Chatsidis, Georgios, Rizos, Georgios, Papakotoulas, Pavlos
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
719 Phase 1 study of the porcupine (PORCN) inhibitor RXC004 in combination with the PD-1 inhibitor nivolumab in patients with advanced solid tumors
Cook, Natalie, Blagden, Sarah, Lopez, Juanita, Sarker, Debashis, Greystoke, Alastair, Bashir, Saira, Skolariki, Aglaia, ElBadri, Salma, Morton, Cienne, OrtegoFranco, Ana, MohamedKhan, Shybi, Eagle, Catherine, Flanagan, Eimear, Goodwin, Louise, Phillips, Caroline, Robertson, Jane, Tilston, Craig, Timmis, Helen, Woodcock, Simon, Plummer, Ruth
Published in Journal for immunotherapy of cancer (01.11.2022)
Published in Journal for immunotherapy of cancer (01.11.2022)
Get full text
Journal Article
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)
Khan, Khurum, Mukherjee, Uma, Schlechter, Benjamin L, Ciombor, Kristen K, Skolariki, Aglaia, Coveler, Andrew L, Graham, Janet S, Peters, Mary Linton, Cohen, Stacey A, Mettu, Niharika, Marijon, Hélène, Cosgrove, David, McKissock, Fiona G, Oelmann, Elisabeth, Bloss, Jeffrey D, Blagden, Sarah P, de Gramont, Aimery, Berlin, Jordan, Evans, T.R. Jeffry
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article
Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study
Blagden, Sarah P, Symeonides, Stefan N, Skolariki, Aglaia, Haris, Noor Md, Boh, Zhuang, Um, In Hwa, Elshani, Mustafa, Dickson, Alison L, Zhang, Ying, Harrison, David J, McKissock, Fiona G, Oelmann, Elisabeth, Bloss, Jeffrey D, Cook, Natalie, Evans, TR Jeffry, Plummer, E. Ruth
Published in Molecular cancer therapeutics (01.12.2023)
Published in Molecular cancer therapeutics (01.12.2023)
Get full text
Journal Article